eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
3/2022
vol. 39
 
Share:
Share:
more
 
 
abstract:
Original paper

Efficacy and safety of dupilumab in the treatment of moderate-to-severe atopic dermatitis: a meta-analysis of randomized controlled trials

Shuying Wu
1, 2
,
Huiping Wang
1

1.
Department of Dermatovenereology, Tianjin Medical University General Hospital/Tianjin Institute of Sexually Transmitted Disease, Tianjin, China
2.
Department of Dermatology, Tianjin Union Medical Center, Tianjin, China
Adv Dermatol Allergol 2022; XXXIX (3): 601-610
Online publish date: 2022/07/14
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction
Patients with atopic dermatitis (AD) have high disease burden negatively affecting quality of life. Aim: To assess the efficacy and safety of dupilumab in patients with moderate-to-severe AD.

Material and methods
A systematic literature search was performed using the main-stream databases of PubMed, Web of Science, and Embase. Standard mean difference (SMD) or risk ratios (RR) with 95% confidence interval (95% CI) were calculated using a fixed-effects or random-effects model.

Results
A total of 11 studies with 4094 patients met the inclusion criteria and were included in this meta-analysis. Pooled estimate showed that dupilumab significantly improved the mean change in the Eczema Area and Severity Index (EASI) score (SMD = –10.90, 95% CI: –12.13, –9.68; p < 0.001), percentage of body surface area (BSA) affected (SMD = –10.87, 95% CI: –13.04, –8.70; p < 0.001), pruritus numeric rating scale (NRS) scores (SMD = –9.29, 95% CI: –10.34, –8.25; p < 0.001), and Dermatology Life Quality Index (DLQI) scores (SMD = –9.66, 95% CI: –11.50, –7.82; p < 0.001). In addition, dupilumab was associated with a significantly higher Investigator’s Global Assessment (IGA) response (RR = 3.57, 95% CI: 2.53, 5.03; p < 0.001). The overall incidence of adverse events was comparable between dupilumab and other treatments (RR = 1.00, 95% CI: 0.96, 1.03; p = 0.832). However, the injection-site reaction, headache and conjunctivitis were more frequently seen in patients treated with dupilumab.

Conclusions
Dupilumab is well tolerated, and could improve signs and symptoms of AD. However, the results should be interpreted cautiously since there was significant heterogeneity among the studies.

keywords:

atopic dermatitis, dupilumab, meta-analysis

Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.